PRODUCT INFORMATION



Cyclin D1 Rabbit Monoclonal Antibody (Clone RM241)

Item No. 32195

Overview and Properties

Contents: This vial contains 100 µl of protein A-affinity purified monoclonal antibody.

Immunogen: Peptide corresponding to cyclin D1

Species Reactivity: (+) Human Form: Liquid

-20°C (as supplied) Storage:

Stability: ≥1 year

PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide Storage Buffer:


Clone: Rabbit Host: **IgG** Isotype:

Applications: Immunohistochemistry (IHC) and Western blot (WB); the recommended starting

dilution is 1:500-1:1,000 for IHC and 1:1,000-1:2,000 for WB. Other applications were not tested, therefore optimal working concentration/dilution should be determined


empirically.

Images




Lane 1: HeLa cell lysates


WB of HeLa cell lysates using Cyclin D1 Rabbit Monoclonal Antibody (Clone RM241) at a dilution



Immunohistochemical staining of formalin-fixed and paraffin-embedded human tonsil tissue using Cyclin D1 Rabbit Monoclonal Antibody (Clone RM241) at a 1:1,000 dilution.



and paraffin-embedded human breast cancer sections using Cyclin D1 Rabbit Monoclonal Antibody (Clone RM241) at a 1:1,000 dilution



Immunohistochemical staining of formalin-fixed and paraffin-embedded human mantle cell lymphoma tissue using Cyclin D1 Rabbit Monoclonal Antibody (Clone RM241) at a 1:1,000

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 01/19/2024

CAYMAN CHEMICAL 1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Cyclin D1 is a regulatory protein that controls cell proliferation by promoting cell cycle progression from G_1 to S phase. It is induced during the G_1 phase following stimulation with mitogens, including growth factors, hormones, and cytokines, and heterodimerizes with cyclin-dependent kinase 4 (Cdk4) or Cdk6 in the cytoplasm. Protein D1/Cdk4/6 complex translocates to the nucleus and phosphorylates retinoblastoma protein (Rb), permitting expression of E2F transcription factors, which drive S phase entry and progression. During the G_1 /S phase transition, cyclin D1 is phosphorylated by glycogen synthase kinase 3 β (GSK3 β) and exported to the cytoplasm where it is ubiquitinated and degraded. *CCND1*, the gene encoding cyclin D1, is overexpressed in a variety of human cancers, including mantle cell lymphoma, pancreatic cancer, and breast cancer, and tumor cyclin D1 levels are increased in patients with colorectal cancer and associated with decreased overall survival. Section D1 Rabbit Monoclonal Antibody (Clone RM241) can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes cyclin D1 at approximately 34 kDa from human samples.

References

- 1. Qie, S. and Diehl, J.A. Cyclin D1, cancer progression, and opportunities in cancer treatment. J. Mol. Med. (Berl.) 94(12), 1313-1326 (2016).
- 2. Fu, M., Wang, C., Li, Z., et al. Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 145(12), 5439-5447 (2004).
- 3. Gladden, A.B and Diehl, J.A. Location, location, location: The role of cyclin D1 nuclear localization in cancer. J. Cell. Biochem. 96(5), 906-913 (2005).
- 4. Kim, J.K. and Diehl, J.A. Nuclear cyclin D1: An oncogenic driver in human cancer. J. Cell. Physiol. 220(2), 292-296 (2009).
- 5. Musgrove, E.A., Caldon, C.E., Barraclough, J., et al. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11(8), 558-572 (2011).
- 6. McKay, J.A., Douglas, J.J., Ross, V.G., et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Int. J. Cancer 88(1), 77-91 (2000).

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335